Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 1199

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 1199
---
 proceeding) is asserted by such director, officer, or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

<div align='center'>II-11</div>

TABLE OF CONTENTS

SIGNATURES Pursuant to the requirements of the Securities Act, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-4 and has duly caused this Registration Statement to be signed on its behalf by the undersigned thereunto duly authorized, in the city of Stamford, State of Connecticut, on this 13th day of February, 2025. CARA THERAPEUTICS, INC. By: /s/ Christopher Posner Christopher Posner
President and Chief Executive Officer Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

| ​ 
 ​ 
 ​ | Signature              
 /s/ Christopher Posner 
 ​                      
 Christopher Posner     
 /s/ Ryan Maynard       
 ​                      
 Ryan Maynard           | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Title                                                                           
 President and Chief Executive Officer and Director(Principal Executive Officer) 
 Chief Financial Officer(Principal Financial and Accounting Officer)             | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Date              
 February 13, 2025 
 February 13, 2025 | ​ 
 ​ 
 ​ |
|:--|:-----------------------|:--|:--|:--------------------------------------------------------------------------------|:--|:--|:------------------|:--|
| ​ | *                      
 ​                      
 Martin Vogelbaum       | ​ | ​ | Chairman of the Board                                                           | ​ | ​ | February 13, 2025 | ​ |
| ​ | *                      
 ​                      
 Helen Boudreau         | ​ | ​ | Director                                                                        | ​ | ​ | February 13, 2025 | ​ |
| ​ | *                      
 ​                      
 Jeffrey Ives, Ph.D.    | ​ | ​ | Director                                                                        | ​ | ​ | February 13, 2025 | ​ |
| ​ | *                      
 ​                      
 Lisa von Moltke, M.D.  | ​